Biocom’s top priority is the safety of our members and the well-being of our employees. After careful consideration, Biocom has decided to transform our 2021 Global Life Science Partnering Conference to a fully virtual event. We know that many lives are being impacted and disrupted by COVID-19 and we are grateful to be able to continue offering our members valuable content in a safe manner.
Managing Director, Avalon Ventures; President & CEO, COI Pharmaceutica
Jay B. Lichter, Ph.D. is an experienced biotechnology and pharmaceutical business executive with over 25 years of experience in management, scientific research, and business development. Throughout his career, Dr. Lichter has applied his exceptional combination of business acumen and deep technical knowledge to creating commercially successful biotech companies and identifying the commercial potential of scientific discoveries at their earliest stages. Dr. Lichter is the inventor on over 250 patents and patent applications for several Avalon portfolio companies. Dr. Lichter has been either directly responsible for or participated in licensing or merger and acquisition deals valued in excess of $6 billion.
Dr. Lichter led Avalon XI investments in Fortis Therapeutics, Janux and PDI and led Avalon X investments in Sitari (acquirted by GlaxoSmithKline), Calporta (Acquired by Merck), Synthorx (acquired by Sanofi), Aratana (acquired by Zoetis), Zacharon (acquired by BioMarin) and RQx (licensed to Genentech), as well as others.
Dr. Lichter held postdoctoral positions in Human Genetics at Yale University and pharmacogenetics at DuPont Merck Pharmaceutical Co. Dr. Lichter obtained his Ph.D. in biochemistry from the University of Illinois at Chicago, and a B.S. from the Univ. of Illinois at Urbana-Champaign.